Voorbeelden van het gebruik van Zykadia in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
How is Zykadia used?
Other information about Zykadia.
Why is Zykadia approved?
Blood tests during treatment with Zykadia.
Zykadia has been given‘conditional approval.
Table 2 ADRs in patients treated with Zykadia at a dose of 750 mg.
Zykadia with dose reduced by one decrement.
It may make the amount of Zykadia in your blood increase to a harmful level.
Zykadia should not be used during breast-feeding.
The median duration of exposure to Zykadia was 33.0 weeks range:
What Zykadia looks like and contents of the pack?
However, the evidence was insufficient to support the use of Zykadia in these patients.
Zykadia should be discontinued in patients unable to tolerate 300 mg daily.
If you have questions about how long to take Zykadia, talk to your doctor or pharmacist.
Use of Zykadia in patients with congenital long QT syndrome should be avoided.
Your doctor may need to adjust your treatment or stop Zykadia temporarily or permanently.
The use of Zykadia in children and adolescents up to 18 years of age is not recommended.
Your doctor will discuss with you the potential risks of taking Zykadia during pregnancy.
Table 1 Zykadia dose adjustment and management recommendations for ADRs.
Avoid concomitant use of strong CYP3A inhibitors during treatment with Zykadia see section 4.5.
Zykadia blocks the action of this abnormal protein
These medicines should be used with care or may need to be avoided during your treatment with Zykadia.
Temporary dose interruption and/or dose reduction of Zykadia may be required based on individual safety and tolerability.
The potential for QT interval prolongation of ceritinib was assessed in four clinical studies with Zykadia.
you are prescribed a new medicine that you have not already taken at the same time as Zykadia.
permanently discontinue Zykadia.
amylase elevations prior to the start of Zykadia treatment and periodically thereafter as clinically indicated see sections 4.2 and 4.8.
Zykadia should be permanently discontinued in patients who develop QTc>
reduction or discontinuation of Zykadia in the management of selected ADRs.
In one study 56% of patients given Zykadia(92 of 163)